TCGA-95-7562-01A-11R-2241-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V1+0.440
- MTORC1_SIGNALING+0.390
- INTERFERON_ALPHA_RESPONSE+0.370
- GLYCOLYSIS+0.350
- PROTEIN_SECRETION+0.330
- ANDROGEN_RESPONSE+0.320
- OXIDATIVE_PHOSPHORYLATION+0.320
- DNA_REPAIR+0.310
Top 10 suppressed
- MYOGENESIS-0.310
- ANGIOGENESIS-0.280
- KRAS_SIGNALING_DN-0.250
- TNFA_SIGNALING_VIA_NFKB-0.190
- APICAL_SURFACE-0.150
- TGF_BETA_SIGNALING-0.150
- COAGULATION-0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- XENOBIOTIC_METABOLISM-0.140
- IL6_JAK_STAT3_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579805 | — | C | 0.860 |
| 2 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.853 |
| 3 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.852 |
| 4 | d5610bbc-93c5-4ca5-b687-f955d1b84c92 | — | — | 0.852 |
| 5 | 88318 | EPN | Supratentorial EPN | 0.851 |
| 6 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.841 |
| 7 | SRR6013495 | — | cohortA1 | 0.836 |
| 8 | SRR17866821 | — | — | 0.834 |
| 9 | SRR934915 | — | — | 0.831 |
| 10 | TCGA-A8-A09W-01A-11R-A00Z-07 | — | B | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |